mTOR signaling in disease

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590

The hallmarks of cancer

Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219

Sorafenib in advanced hepatocellular carcinoma

Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097

Mutations of the BRAF gene in human cancer

Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674

TOR signaling in growth and metabolism

Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787

Sorafenib in Advanced Hepatocellular Carcinoma

정, 재. (2008) · Cited by 5,586

ras oncogenes in human cancer: a review.

Bos, J. L. (1989) · PubMed · Cited by 5,061

A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization

Morice, M., Serruys, P. W. J. C., Sousa, J. E., Fajadet, J. C., Hayashi, E. B., Perin, M. A., Colombo, A., Schuler, G. C., Barragan, P. T., Guagliumi, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012843 · Cited by 4,028

mTOR: from growth signal integration to cancer, diabetes and ageing

Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941

TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival

Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914

AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint

Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849

Rapamycin fed late in life extends lifespan in genetically heterogeneous mice

Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease

Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604

High Frequency of Mutations of the PIK3CA Gene in Human Cancers

Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A. F., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,448

Targeting RAS signalling pathways in cancer therapy

Downward, J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc969 · Cited by 3,354

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330

A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance

Newgard, C. B., An, J., Bain, J. R., Muehlbauer, M. J., Stevens, R. D., Lien, L. F., Haqq, A. M., Shah, S. H., Arlotto, M., Slentz, C. A., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.02.002 · Cited by 3,165

mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists

Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788

Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB

Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365

Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease

Ravikumar, B., Vacher, C., Berger, Z., Davies, J. E., Luo, S., Oroz, L. G., Scaravilli, F., Easton, D. F., Duden, R., O'Kane, C. J., et al. (2004) · Nature Genetics · doi:10.1038/ng1362 · Cited by 2,347

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Rüegg, M. A., Hall, A., & Hall, M. N. (2004) · Nature Cell Biology · doi:10.1038/ncb1183 · Cited by 2,097

Activation of a metabolic gene regulatory network downstream of mTOR complex 1

Düvel, K., Yecies, J. L., Menon, S., Raman, P., Lipovsky, A. I., Souza, A. L., Triantafellow, E., Ma, Q., Gorski, R., Cleaver, S., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.06.022 · Cited by 2,020

Ras, PI(3)K and mTOR signalling controls tumour cell growth

Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019

Two TOR Complexes, Only One of which Is Rapamycin Sensitive, Have Distinct Roles in Cell Growth Control

Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P., & Hall, M. N. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00636-6 · Cited by 1,886

PI3K pathway alterations in cancer: variations on a theme

Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1

Thoreen, C. C., Kang, S. A., Chang, J. W., Liu, Q., Zhang, J., Gao, Y., Reichling, L. J., Sim, T., Sabatini, D. M., & Gray, N. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900301200 · Cited by 1,803

High frequency of BRAF mutations in nevi

Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730

Promoting Axon Regeneration in the Adult CNS by Modulation of the PTEN/mTOR Pathway

Park, K. K., Liu, K., Hu, Y., Smith, P. D., Wang, C., Cai, B., Xu, B., Connolly, L., Kramvis, I., Sahin, M., et al. (2008) · Science · doi:10.1126/science.1161566 · Cited by 1,686

Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity

Um, S. H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Fumagalli, S., Allegrini, P. R., Kozma, S. C., Auwerx, J., et al. (2004) · Nature · doi:10.1038/nature02866 · Cited by 1,677

ULK1·ATG13·FIP200 Complex Mediates mTOR Signaling and Is Essential for Autophagy

Ganley, I. G., Lam, D. H., Wang, J., Ding, X., Chen, S., & Jiang, X. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900573200 · Cited by 1,447

SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth

Porstmann, T., Santos, C. R., Griffiths, B., Cully, M., Wu, M., Leevers, S., Griffiths, J. R., Chung, Y.-L., & Schulze, A. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.07.007 · Cited by 1,413

TSC2 Integrates Wnt and Energy Signals via a Coordinated Phosphorylation by AMPK and GSK3 to Regulate Cell Growth

Inoki, K., Ouyang, H., Zhu, T., Lindvall, C., Wang, Y., Zhang, X., Yang, Q., Bennett, C., Harada, Y., Stankunas, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.06.055 · Cited by 1,377

mTOR differentially regulates effector and regulatory T cell lineage commitment

Delgoffe, G. M., Kole, T., Zheng, Y., Zarek, P. E., Matthews, K., Xiao, B., Worley, P., Kozma, S., & Powell, J. (2009) · Immunity · doi:10.1016/j.immuni.2009.04.014 · Cited by 1,293

Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway

Kapahi, P., Zid, B. M., Harper, T., Koslover, D., Sapin, V., & Benzer, S. (2004) · Current Biology · doi:10.1016/j.cub.2004.03.059 · Cited by 1,293

Regulation of Yeast Replicative Life Span by TOR and Sch9 in Response to Nutrients

Kaeberlein, M., Powers, R. W., Steffen, K. K., Westman, E. A., Hu, D., Dang, N., Kerr, E. O., Kirkland, K. T., Fields, S., & Kennedy, B. K. (2005) · Science · doi:10.1126/science.1115535 · Cited by 1,293

BRAF mutation in thyroid cancer

Xing, M. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.0978 · Cited by 1,293

The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis

Moasser, M. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210477 · Cited by 1,291

Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis

Bissler, J. J., McCormack, F. X., Young, L. R., Elwing, J., Chuck, G., Leonard, J. M., Schmithorst, V. J., Laor, T., Brody, A. S., Bean, J. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa063564 · Cited by 1,250

Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice

Postic, C., & Girard, J. R. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34275 · Cited by 1,243

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

Maira, S.-M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chène, P., De Pover, A., Schoemaker, K., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0017 · Cited by 1,134

mTOR signaling: At the crossroads of plasticity, memory and disease

Hoeffer, C. A., & Klann, E. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2009.11.003 · Cited by 1,128

Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2

Feldman, M. E., Apsel, B., Uotila, A., Loewith, R., Knight, Z. A., Ruggero, D., & Shokat, K. M. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000038 · Cited by 1,111

Tuberous sclerosis

Curatolo, P., Bombardieri, R., & Jóźwiak, S. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61279-9 · Cited by 1,106

Influence of TOR kinase on lifespan in C. elegans

Vellai, T., Takacs-Vellai, K., Zhang, Y., Kovacs, A. L., Orosz, L., & Müller, F. (2003) · Nature · doi:10.1038/426620a · Cited by 1,057

Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease

Spilman, P., Podlutskaya, N., Hart, M. J., Debnath, J., Gorostiza, O., Bredesen, D., Richardson, A., Strong, R., & Galvan, V. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009979 · Cited by 1,033

Mutation of the PIK3CA Gene in Ovarian and Breast Cancer

Campbell, I., Russell, S. E., Choong, D. Y. H., Montgomery, K. G., Ciavarella, M. L., Hooi, C. S. F., Cristiano, B. E., Pearson, R. B., & Phillips, W. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2933 · Cited by 917

Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis

Ehninger, D., Han, S., Shilyansky, C., Zhou, Y., Li, W., Kwiatkowski, D. J., Ramesh, V., & Silva, A. J. (2008) · Nature Medicine · doi:10.1038/nm1788 · Cited by 882

The role of signaling pathways in the development and treatment of hepatocellular carcinoma

Whittaker, S. R., Marais, R., & Zhu, A. X. (2010) · Oncogene · doi:10.1038/onc.2010.236 · Cited by 841

Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation

Choo, A. Y., Yoon, S.-O., Kim, S. G., Roux, P. P., & Blenis, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809136105 · Cited by 829

Altered PTEN Expression as a Diagnostic Marker for the Earliest Endometrial Precancers

Mutter, G. L. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.11.924 · Cited by 829

Guilty as charged

Garnett, M. J., & Marais, R. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.022 · Cited by 822

The TSC-mTOR Signaling Pathway Regulates the Innate Inflammatory Response

Weichhart, T., Costantino, G., Poglitsch, M., Rosner, M., Zeyda, M., Stuhlmeier, K. M., Kolbe, T., Stulnig, T. M., Hörl, W. H., Hengstschläger, M., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.08.012 · Cited by 801

PTEN loss in the continuum of common cancers, rare syndromes and mouse models

Hollander, M. C., Blumenthal, G. M., & Dennis, P. A. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3037 · Cited by 793

eIF-4E expression and its role in malignancies and metastases

Benedetti, A. D., & Graff, J. R. (2004) · Oncogene · doi:10.1038/sj.onc.1207545 · Cited by 751

AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas.

Cheng, J. Q., Godwin, A. K., Bellacosa, A., Taguchi, T., Franke, T. F., Hamilton, T. C., Tsichlis, P. N., & Testa, J. R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.19.9267 · Cited by 737

Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis

Li, S., Brown, M. S., & Goldstein, J. L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914798107 · Cited by 733

Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies.

Tashiro, H., Blazes, M. S., Wu, R., Cho, K. R., Bose, S., Wang, S. I., Li, J., Parsons, R. E., & Ellenson, L. H. (1997) · PubMed · Cited by 701

Akt Stimulates Hepatic SREBP1c and Lipogenesis through Parallel mTORC1-Dependent and Independent Pathways

Yecies, J. L., Zhang, H., Menon, S., Liu, S., Yecies, D. W., Lipovsky, A. I., Görgün, C. Z., Kwiatkowski, D. J., Hotamışlıgil, G. S., Lee, C., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.06.002 · Cited by 685

With TOR, Less Is More: A Key Role for the Conserved Nutrient-Sensing TOR Pathway in Aging

Kapahi, P., Chen, D., Rogers, A. N., Katewa, S. D., Li, P. W.-L., Thomas, E., & Kockel, L. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.05.001 · Cited by 678

PTEN: Life as a Tumor Suppressor

Simpson, L., & Parsons, R. E. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5130 · Cited by 677

Activation of mTORC2 by Association with the Ribosome

Zinzalla, V., Stracka, D., Oppliger, W., & Hall, M. N. (2011) · Cell · doi:10.1016/j.cell.2011.02.014 · Cited by 648

mTORC1 controls fasting-induced ketogenesis and its modulation by ageing

Sengupta, S., Peterson, T. R., Laplante, M., Oh, S., & Sabatini, D. M. (2010) · Nature · doi:10.1038/nature09584 · Cited by 646

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Heß, G., Herbrecht, R., Romaguera, J. E., Verhoef, G. E. G., Crump, M., Gisselbrecht, C., Laurell, A., Offner, F. C., Strahs, A. L., Berkenblit, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7977 · Cited by 641

Skeletal Muscle-Specific Ablation of raptor, but Not of rictor, Causes Metabolic Changes and Results in Muscle Dystrophy

Bentzinger, C. F., Romanino, K., Cloëtta, D., Lin, S., Mascarenhas, J. B., Oliveri, F., Xia, J., Casanova, E., Costa, C. F., Brink, M., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.10.002 · Cited by 640

PTEN Mutation, EGFR Amplification, and Outcome in Patients With Anaplastic Astrocytoma and Glioblastoma Multiforme

Smith, J. S., Tachibana, I., Passe, S. M., Huntley, B. K., Borell, T. J., Iturria, N. L., O'Fallon, J. R., Schaefer, P., Scheithauer, B. W., James, C. D., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.16.1246 · Cited by 630

The Mammalian Target of Rapamycin (mTOR) Pathway Regulates Mitochondrial Oxygen Consumption and Oxidative Capacity

Schieke, S. M., Phillips, D., McCoy, J. P., Aponte, A. M., Shen, R.-F., Balaban, R. S., & Finkel, T. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603536200 · Cited by 623

Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1

Ben Sahra, I., Regazzetti, C., Robert, G., Laurent, K., Le Marchand-Brustel, Y., Auberger, P., Tanti, J.-F., Giorgetti-Peraldi, S., & Bost, F. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1769 · Cited by 616

Increased Activation of the Mammalian Target of Rapamycin Pathway in Liver and Skeletal Muscle of Obese Rats: Possible Involvement in Obesity-Linked Insulin Resistance

Khamzina, L., Veilleux, A., Bergeron, S., & Marette, A. (2005) · Endocrinology · doi:10.1210/en.2004-0921 · Cited by 562

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging

Steelman, L. S., Chappell, W. H., Abrams, S. L., Kempf, C. R., Long, J., Laidler, P., Mijatovic, S., Maksimovic-Ivanic, D., Stivala, F., Mazzarino, M. C., et al. (2011) · Aging · doi:10.18632/aging.100296 · Cited by 553

4E-BP Extends Lifespan upon Dietary Restriction by Enhancing Mitochondrial Activity in Drosophila

Zid, B. M., Rogers, A. N., Katewa, S. D., Vargas, M. A., Kolipinski, M., Lu, T. A., Benzer, S., & Kapahi, P. (2009) · Cell · doi:10.1016/j.cell.2009.07.034 · Cited by 548

Role of mTOR in podocyte function and diabetic nephropathy in humans and mice

Gödel, M., Hartleben, B., Herbach, N., Liu, S., Zschiedrich, S., Lu, S., Debreczeni-Mór, A., Lindenmeyer, M. T., Rastaldi, M.-P., Hartleben, G., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44774 · Cited by 547

mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice

Inoki, K., Mori, H., Wang, J., Suzuki, T., Hong, S., Yoshida, S., Blattner, S. M., Ikenoue, T., Rüegg, M. A., Hall, M. N., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44771 · Cited by 538

Untitled work

(1997) · PubMed · Cited by 512

PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas

Lee, J. W., Soung, Y. H., Kim, S. Y., Lee, H. W., Park, W. S., Nam, S. W., Kim, S. H., Lee, J. Y., Yoo, N. J., & Lee, S. H. (2004) · Oncogene · doi:10.1038/sj.onc.1208304 · Cited by 508

The Mammalian Target of Rapamycin: Linking T Cell Differentiation, Function, and Metabolism

Powell, J. D., & Delgoffe, G. M. (2010) · Immunity · doi:10.1016/j.immuni.2010.09.002 · Cited by 503

Adipose-Specific Knockout of raptor Results in Lean Mice with Enhanced Mitochondrial Respiration

Polak, P., Cybulski, N., Feige, J. N., Auwerx, J., Rüegg, M. A., & Hall, M. N. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.09.003 · Cited by 480

Survival of acute myeloid leukemia cells requires PI3 kinase activation

Xu, Q., Simpson, S.-E., Scialla, T. J., Bagg, A., & Carroll, M. P. (2003) · Blood · doi:10.1182/blood-2002-11-3429 · Cited by 473

High Frequency of Coexistent Mutations of PIK3CA and PTEN Genes in Endometrial Carcinoma

Oda, K., Stokoe, D., Taketani, Y., & McCormick, F. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2620 · Cited by 467

Rapamycin Protects against Neuron Death inIn VitroandIn VivoModels of Parkinson's Disease

Malagelada, C., Jin, Z. H., Jackson-Lewis, V. R., Przedborski, S., & Greene, L. A. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.3944-09.2010 · Cited by 465

Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases

Apsel, B., Blair, J. A., González, B., Nazif, T. M., Feldman, M. E., Aizenstein, B., Hoffman, R., Williams, R. L., Shokat, K. M., & Knight, Z. A. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.117 · Cited by 460

Toll-like receptor–mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway

Cao, W., Manicassamy, S., Tang, H., Kasturi, S. P., Pirani, A. M., Murthy, N., & Pulendran, B. (2008) · Nature Immunology · doi:10.1038/ni.1645 · Cited by 416

Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era

Pérez‐Galán, P., Dreyling, M. H., & Wiestner, A. U. (2010) · Blood · doi:10.1182/blood-2010-04-189977 · Cited by 394

PTEN gene mutations are seen in high-grade but not in low-grade gliomas.

Rasheed, B., Stenzel, T. T., McLendon, R. E., Parsons, R. E., Friedman, A. H., Friedman, H. S., Bigner, D. D., & Bigner, S. H. (1997) · PubMed · Cited by 384

Metformin: Taking away the candy for cancer?

Jalving, M., Gietema, J. A., Lefrandt, J. D., de Jong, S., Reyners, A. K. L., Gans, R. O. B., & de Vries, E. G. E. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.06.012 · Cited by 382

Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin

Knight, S. D., Adams, N. D., Burgess, J. L., Chaudhari, A. M., Darcy, M. G., Donatelli, C. A., Luengo, J. I., Newlander, K. A., Parrish, C. A., Ridgers, L. H., et al. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml900028r · Cited by 378

Astrocyte‐specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures

Uhlmann, E. J., Wong, M., Baldwin, R. L., Bajenaru, M. L., Onda, H., Kwiatkowski, D. J., Yamada, K., & Gutmann, D. H. (2002) · Annals of Neurology · doi:10.1002/ana.10283 · Cited by 372

mTORC2 can associate with ribosomes to promote cotranslational phosphorylation and stability of nascent Akt polypeptide

Oh, W. J., Wu, C. C., Kim, S. J., Facchinetti, V., Julien, L.-A., Finlan, M., Roux, P. P., Su, B., & Jacinto, E. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.271 · Cited by 354

Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells

Cao, K., Graziotto, J. J., Blair, C. D., Mazzulli, J. R., Erdos, M. R., Krainc, D., & Collins, F. S. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002346 · Cited by 350

Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2

Bacquer, O. L., Petroulakis, E., Paglialunga, S., Poulin, F., Richard, D., Cianflone, K., & Sonenberg, N. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29528 · Cited by 348

Common corruption of the mTOR signaling network in human tumors

Menon, S., & Manning, B. D. (2008) · Oncogene · doi:10.1038/onc.2009.352 · Cited by 345

PTEN mutations in gliomas and glioneuronal tumors

Duerr, E., Rollbrocker, B., Hayashi, Y., Peters, N., Meyer‐Puttlitz, B., Louis, D. N., Schramm, J., Wiestler, O. D., Parsons, R. E., Eng, C., et al. (1998) · Oncogene · doi:10.1038/sj.onc.1201756 · Cited by 345

Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin

Yu, K., Toral‐Barza, L., Shi, C., Zhang, W., Lucas, J., Shor, B., Kim, J., Verheijen, J. C., Curran, K. J., Malwitz, D. J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0299 · Cited by 344

MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice

Zhang, D., Contu, R., Latronico, M. V. G., Zhang, J. L., Rizzi, R., Catalucci, D., Miyamoto, S., Huang, K., Ceci, M., Gu, Y., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43008 · Cited by 338

Incidence and prognosis of c‐KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias

Care, R. S., Valk, P. J. M., Goodeve, A. C., Abuduhier, F. M., Geertsma-Kleinekoort, W. M. C., Wilson, G. A., Gari, M. A., Peake, I. R., Löwenberg, B., & Reilly, J. T. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04362.x · Cited by 322

Rapamycin reduces disease activity and normalizes T cell activation–induced calcium fluxing in patients with systemic lupus erythematosus

Fernández, D., Bonilla, E., Mirza, N., Niland, B. P., & Perl, A. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22085 · Cited by 321

K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study

Brink, M. (2003) · Carcinogenesis · doi:10.1093/carcin/bgg009 · Cited by 314

bcl-1, t(11;14), and mantle cell-derived lymphomas [editorial]

Raffeld, M. A., & Jaffe, E. (1991) · Blood · doi:10.1182/blood.v78.2.259.bloodjournal782259 · Cited by 303

Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions

Balsara, B. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh226 · Cited by 293

The Translation Repressor 4E-BP2 Is Critical for eIF4F Complex Formation, Synaptic Plasticity, and Memory in the Hippocampus

Banko, J. L., Poulin, F., Hou, L., DeMaria, C. T., Sonenberg, N., & Klann, E. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2423-05.2005 · Cited by 290

A role for mammalian target of rapamycin in regulating T cell activation versus anergy

Zheng, Y., Collins, S. L., Lutz, M. A., Allen, A. N., Kole, T. P., Zarek, P. E., & Powell, J. D. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.4.2163 · Cited by 274

The multiple facets of mTOR in immunity

Weichhart, T., & Säemann, M. D. (2009) · Trends in Immunology · doi:10.1016/j.it.2009.02.002 · Cited by 263

TOR-dependent control of autophagy: biting the hand that feeds

Neufeld, T. P. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.11.005 · Cited by 261

Fat Cell–Specific Ablation of Rictor in Mice Impairs Insulin-Regulated Fat Cell and Whole-Body Glucose and Lipid Metabolism

Kumar, A. T., Lawrence, J. C., Jung, D. Y., Ko, H. J., Keller, S. R., Kim, J. K., Magnuson, M. A., & Harris, T. E. (2010) · Diabetes · doi:10.2337/db09-1061 · Cited by 259

Cardiac Raptor Ablation Impairs Adaptive Hypertrophy, Alters Metabolic Gene Expression, and Causes Heart Failure in Mice

Shende, P., Plaisance, I., Morandi, C., Pellieux, C., Berthonneche, C., Zorzato, F., Krishnan, J., Lerch, R. A., Hall, M. N., Rüegg, M. A., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.977066 · Cited by 239

In ovarian neoplasms, BRAF , but not KRAS , mutations are restricted to low‐grade serous tumours

Sieben, N. L. G., Macropoulos, P., Roemen, G. M. J. M., Kolkman-Uljee, S. M., Fleuren, G. J., Houmadi, R., Diss, T. C., Warren, B. K., Al‐Adnani, M., de Goeij, A. F. P. M., et al. (2004) · The Journal of Pathology · doi:10.1002/path.1521 · Cited by 237

Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders

Ehninger, D., & Silva, A. J. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.10.002 · Cited by 223

Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer

Sato, T., Nakashima, A., Guo, L., Coffman, K., & Tamanoi, F. (2010) · Oncogene · doi:10.1038/onc.2010.28 · Cited by 223

Phosphoinositide-3 Kinase Signaling in Cardiac Hypertrophy and Heart Failure

Aoyagi, T., & Matsui, T. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211796390976 · Cited by 218

Disruption of Tsc2 in pancreatic β cells induces β cell mass expansion and improved glucose tolerance in a TORC1-dependent manner

Rachdi, L., Balcázar, N., Osorio-Duque, F., Elghazi, L., Weiss, A., Gould, A. P., Chang-Chen, K. J., Gambello, M. J., & Bernal‐Mizrachi, E. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803047105 · Cited by 217

PIK3CA mutations in human solid tumors: Role in sensitivity to various therapeutic approaches

Ligresti, G., Militello, L., Steelman, L. S., Cavallaro, A., Basile, F., Nicoletti, F., Stivala, F., McCubrey, J. A., & Libra, M. (2009) · Cell Cycle · doi:10.4161/cc.8.9.8255 · Cited by 214

Growth and aging: a common molecular mechanism

Blagosklonny, M. V., & Hall, M. N. (2009) · Aging · doi:10.18632/aging.100040 · Cited by 214

The Multifunctional Role of mTOR in Innate Immunity: Implications for Transplant Immunity

Säemann, M. D., Haidinger, M., Hecking, M., Hörl, W. H., & Weichhart, T. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02832.x · Cited by 212

Calorie restriction: Decelerating mTOR-driven aging from cells to organisms (including humans)

Blagosklonny, M. V. (2010) · Cell Cycle · doi:10.4161/cc.9.4.10766 · Cited by 211

Neuropathology of tuberous sclerosis

Mizuguchi, M., & Takashima, S. (2001) · Brain and Development · doi:10.1016/s0387-7604(01)00304-7 · Cited by 205

Clinicopathologic factors associated with HER2‐positive gastric cancer and its impact on survival outcomes—A systematic review

Chua, T. C., & Merrett, N. D. (2011) · International Journal of Cancer · doi:10.1002/ijc.26292 · Cited by 201

PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma

Qiu, W., Schönleben, F., Li, X., Ho, D. J., Close, L. G., Manolidis, S. L., Bennett, B. P., & Su, G. H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2173 · Cited by 200

MicroRNA in Cancer: The Involvement of Aberrant MicroRNA Biogenesis Regulatory Pathways

Davis‐Dusenbery, B. N., & Hata, A. (2010) · Genes & Cancer · doi:10.1177/1947601910396213 · Cited by 199

RTP801 Is Elevated in Parkinson Brain Substantia Nigral Neurons and Mediates Death in Cellular Models of Parkinson's Disease by a Mechanism Involving Mammalian Target of Rapamycin Inactivation

Malagelada, C., Ryu, E. J., Biswas, S. C., Jackson-Lewis, V. R., & Greene, L. A. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.3292-06.2006 · Cited by 190

Critical Role for Hypothalamic mTOR Activity in Energy Balance

Mori, H., Inoki, K., Münzberg, H., Opland, D. M., Faouzi, M., Villanueva, E. C., Ikenoue, T., Kwiatkowski, D. J., MacDougald, O. A., Myers, M. G., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.03.005 · Cited by 189

Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms

Nakayama, K., Nakayama, N., Kurman, R. J., Cope, L., Pohl, G., Samuels, Y., Velculescu, V. E., Wang, T., & Shih, I. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.7.2751 · Cited by 187

Rapamycin suppresses seizures and neuronal hypertrophy in a mouse model of cortical dysplasia

Ljungberg, M. C., Sunnen, C. N., Lugo, J. N., Anderson, A. E., & D’Arcangelo, G. (2009) · Disease Models & Mechanisms · doi:10.1242/dmm.002386 · Cited by 186

mTOR links oncogenic signaling to tumor cell metabolism

Yecies, J. L., & Manning, B. D. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0726-6 · Cited by 183

Targeting the mTOR kinase domain: the second generation of mTOR inhibitors

Zhang, Y.-J., Duan, Y.-W., & Zheng, X.-F. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.02.008 · Cited by 176

Therapeutic approaches to epileptogenesis—Hope on the horizon

Pitkänen, A. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2010.02602.x · Cited by 175

mTOR complex 2 in adipose tissue negatively controls whole-body growth

Cybulski, N., Polak, P., Auwerx, J. H., Rüegg, M. A., & Hall, M. N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811321106 · Cited by 175

Transcriptional Control of Cellular Metabolism by mTOR Signaling

Yecies, J. L., & Manning, B. D. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4158 · Cited by 166

Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin.

Ly, C., Arechiga, A. F., Melo, J. V., Walsh, C. M., & Ong, S. T. (2003) · PubMed · Cited by 154

Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer.

Terakawa, N., Kanamori, Y., & Yoshida, S. (2003) · Endocrine Related Cancer · doi:10.1677/erc.0.0100203 · Cited by 151

Inhibition of Mammalian Target of Rapamycin Reverses Alveolar Epithelial Neoplasia Induced by Oncogenic K-ras

Wislez, M., Spencer, L., Izzo, J. G., Juroske, D. M., Balhara, K. S., CODY, D. D., Price, R. E., Hittelman, W. N., Wistuba, I. I., & Kurie, J. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4420 · Cited by 150

Mutation and Allelic Loss of the PTEN/MMAC1 gene in Primary and Metastatic Melanoma Biopsies

Birck, A., Ahrenkiel, V., Zeuthen, J., HOU-JENSEN, K., & Guldberg, P. (2000) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2000.00877.x · Cited by 142

A Low Carbohydrate, High Protein Diet Slows Tumor Growth and Prevents Cancer Initiation

Ho, V. W., Leung, K., Hsu, A., Luk, B., Lai, J., Shen, S. Y., Minchinton, A. I., Waterhouse, D., Bally, M. B., Lin, W., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3973 · Cited by 138

Role for mammalian target of rapamycin complex 1 signaling in neuroadaptations underlying alcohol-related disorders

Neasta, J., Hamida, S. B., Yowell, Q. V., Carnicella, S., & Dorit Ron, A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005554107 · Cited by 136

Cowden syndrome

Farooq, A., Walker, L. J., Bowling, J., & Audisio, R. A. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.04.002 · Cited by 128

Granulocyte-Macrophage Colony-Stimulating Factor Is a Chemoattractant Cytokine for Human Neutrophils: Involvement of the Ribosomal p70 S6 Kinase Signaling Pathway

Gómez-Cambronero, J., Horn, J. M., Paul, C. C., & Baumann, M. A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.12.6846 · Cited by 124

Activation and Function of the mTORC1 Pathway in Mast Cells

Kim, M., Kuehn, H. S., Metcalfe, D. D., & Gilfillan, A. M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.7.4586 · Cited by 123

Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase

Brown, K. A., Hunger, N. I., Docanto, M. M., & Simpson, E. R. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0834-y · Cited by 123

TOR on the brain

Garelick, M. G., & Kennedy, B. K. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2010.08.030 · Cited by 120

mTOR signaling: a central pathway to pathogenesis in systemic lupus erythematosus?

Fernández, D., & Perl, A. (2010) · PubMed · Cited by 119

Patterns of epidermal growth factor receptor amplification in malignant gliomas.

Sauter, G., MAEDA, T., Waldman, F. M., Davis, R. L., & Feuerstein, B. G. (1996) · Europe PMC (PubMed Central) · Cited by 112

Behavioral alterations in mice lacking the translation repressor 4E-BP2

Banko, J. L., Merhav, M., Stern, E., Sonenberg, N., Rosenblum, K., & Klann, E. (2006) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2006.08.012 · Cited by 110

Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies

Chapuis, N., Tamburini, J., Green, A. S., Willems, L., Bardet, V., Park, S., Lacombe, C., Mayeux, P., & Bouscary, D. (2010) · Leukemia · doi:10.1038/leu.2010.170 · Cited by 109

MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways

Oneyama, C., Ikeda, J., Okuzaki, D., Suzuki, K., Kanou, T., Shintani, Y., Morii, E., Okumura, M., Aozasa, K., & Okada, M. (2011) · Oncogene · doi:10.1038/onc.2011.63 · Cited by 103

mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3- mutated acute myeloid leukemia cells

Chen, W., Drakos, E., Grammatikakis, I., Schlette, E. J., Jiang, L., Leventaki, V., Staikou-Drakopoulou, E., Patsouris, E., Panayiotidis, P. G., Medeiros, L. J., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-292 · Cited by 102

The Role of the Akt/mTOR Pathway in Tobacco Carcinogen–Induced Lung Tumorigenesis

Memmott, R. M., & Dennis, P. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0234 · Cited by 87

Phosphoinositide 3-kinase signaling is essential for ABL oncogene–mediated transformation of B-lineage cells

Kharas, M. G., Deane, J. A., Wong, S., O’Bosky, K. R., Rosenberg, N. E., Witte, O. N., & Fruman, D. A. (2004) · Blood · doi:10.1182/blood-2003-07-2193 · Cited by 83

Neuroprotective, immunosuppressant and antineoplastic properties of mTOR inhibitors: current and emerging therapeutic options

Pignataro, G., Capone, D., Polichetti, G., Vinciguerra, A., Gentile, A., Renzo, G. D., & Annunziato, L. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.05.003 · Cited by 81

Oncogenes on my mind: ERK and MTOR signaling in cognitive diseases

Krab, L. C., Goorden, S. M. I., & Elgersma, Y. (2008) · Trends in Genetics · doi:10.1016/j.tig.2008.07.005 · Cited by 80

Allelic losses on chromosome arm 10q and mutation of the PTEN ( MMAC1 ) tumour suppressor gene in primary and metastatic malignant melanomas

REIFENBERGER, J., Wolter, M., Bostr�m, J., B�schges, R., Megahed, M., Ruzicka, T., Schulte, K. W., & Reifenberger, G. (2000) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s004280050477 · Cited by 79

Tuberous Sclerosis Complex-1 Deficiency Attenuates Diet-Induced Hepatic Lipid Accumulation

Kenerson, H. L., Yeh, M. M., & Yeung, R. S. W. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018075 · Cited by 74

PTEN inactivation is rare in melanoma tumours but occurs frequently in melanoma cell lines

Pollock, P. M., Walker, G. J., Glendening, J. M., Noy, T. Q., Bloch, N. C., Fountain, J. W., & Hayward, N. K. (2002) · Melanoma Research · doi:10.1097/00008390-200212000-00006 · Cited by 74

mTORC1 signaling in energy balance and metabolic disease

Catania, C., Binder, E., & Cota, D. (2010) · International Journal of Obesity · doi:10.1038/ijo.2010.208 · Cited by 68

EGF receptor mutations in lung cancer: From humans to mice and maybe back to humans

Arteaga, C. L. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.05.014 · Cited by 51

Mammalian Target of Rapamycin Signaling and Autophagy: Roles in Lymphangioleiomyomatosis Therapy

Yu, J. J., Parkhitko, A. A., & Henske, E. P. (2010) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200909-104js · Cited by 51

The Chemopreventive Agent Myoinositol Inhibits Akt and Extracellular Signal-Regulated Kinase in Bronchial Lesions from Heavy Smokers

Han, W., Gills, J. J., Memmott, R. M., Lam, S. C., & Dennis, P. A. (2009) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-08-0209 · Cited by 51

Liver Kinase B1 (LKB1) in the pathogenesis of epithelial cancers

Herrmann, J. L., Byekova, Y. A., Elmets, C. A., & Athar, M. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.01.014 · Cited by 49

The Novel Cyclophilin Binding Compound, Sanglifehrin A, Disassociates G1 Cell Cycle Arrest from Tolerance Induction

Allen, A. N., Zheng, Y., Gardner, L. B., Safford, M., Horton, M. R., & Powell, J. D. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.8.4797 · Cited by 46

Genome-wide shRNA screen reveals increased mitochondrial dependence upon mTORC2 addiction

Colombi, M., Molle, K. D., Benjamin, D., Rattenbacher-Kiser, K. F., Schaefer, C., Betz, C., Thiemeyer, A., Regenass, U., Hall, M. N., & Moroni, C. (2010) · Oncogene · doi:10.1038/onc.2010.539 · Cited by 46

Primary glioblastomas with and without EGFR amplification: Relationship to genetic alterations and clinicopathological features

Benito, R., Gil‐Benso, R., Quilis-Quesada, V., Perez, M., Gregori-Romero, M., Roldán, P., Gonzalez-Darder, J. M., Cerdá‐Nicolás, M., & López‐Ginés, C. (2009) · Neuropathology · doi:10.1111/j.1440-1789.2009.01081.x · Cited by 45

Checks and balances: Interplay of RTKs and PTPs in cancer progression

Sastry, S. K., & Elferink, L. A. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.06.016 · Cited by 43

Clinical activity of mammalian target of rapamycin inhibitors in solid tumors

Alvarado, Y., Mita, M. M., Vemulapalli, S., Mahalingam, D., & Mita, A. C. (2011) · Targeted Oncology · doi:10.1007/s11523-011-0178-5 · Cited by 41

Inhibition of human in-stent restenosis: a molecular view

Giordano, A., & Romano, A. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.03.006 · Cited by 27

Mutation analysis of the human homologue ofdrosophila patched and the xeroderma pigmentosum complementation group A genes in squamous cell carcinomas of the skin

Eklund, L. K., Lindström, E., Undén, A. B., Lundh-Rozell, B., Ståhle‐Bäckdahl, M., Zaphiropoulos, P. G., Toftgård, R., & Söderkvist, P. (1998) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199802)21:2 · Cited by 23

Mammalian target of rapamycin as a target in hematological malignancies

Kelly, K. R., Rowe, J. H., Padmanabhan, S., Nawrocki, S. T., & Carew, J. S. (2011) · Targeted Oncology · doi:10.1007/s11523-011-0175-8 · Cited by 21

Response of Lymphangioleiomyomatosis to a Mammalian Target of Rapamycin Inhibitor (Temsirolimus) –Based Treatment

Piha-Paul, S. A., Hong, D. S., & Kurzrock, R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.5928 · Cited by 14

Review: Hepatocellular carcinoma: the place of new medical therapies

Peck‐Radosavljevic, M. (2010) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x10362278 · Cited by 10

Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib

Wich, C. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i28.3592 · Cited by 9

Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib

CHRISTINA, C., Wich, Abbas, Agaimy, Deike, Strobel, Thaddaus, WissniowskiArndt, Hartmann, C., Matthias, G., et al. (2010) · Acta Scientiarum Naturalium Universitatis Sunyatseni · Cited by 5

mTORC1 and mTORC2 in Energy Homeostasis

Cornu, M., & Hall, M. N. (2010) · The Enzymes · doi:10.1016/s1874-6047(10)28013-7 · Cited by 3

Hepatic mTORC2 Activates Glycolysis and Lipogenesis through Akt, Glucokinase, and SREBP1c

Hagiwara, A., Cornu, M., Cybulski, N., Polak, P., Betz, C., Trapani, F., Terracciano, L., Heim, M. H., Rüegg, M. A., & Hall, M. N. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.03.015 · Cited by 585

Quantitative Phosphoproteomics Reveal mTORC1 Activates de Novo Pyrimidine Synthesis

Robitaille, A. M., Christen, S., Shimobayashi, M., Cornu, M., Fava, L. L., Moes, S., Prescianotto-Baschong, C., Sauer, U., Jenoe, P., & Hall, M. N. (2013) · Science · doi:10.1126/science.1228771 · Cited by 525

Where is mTOR and what is it doing there?

Betz, C., & Hall, M. N. (2013) · The Journal of Cell Biology · doi:10.1083/jcb.201306041 · Cited by 533

SREBPs: metabolic integrators in physiology and metabolism

Jeon, T.-I., & Osborne, T. F. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2011.10.004 · Cited by 464

Mechanisms of Cardiac and Renal Dysfunction in Patients Dying of Sepsis

Takasu, O., Gaut, J. P., Watanabe, E., To, K. B., Fagley, R. E., Sato, B., Jarman, S., Efimov, I. R., Janks, D., Srivastava, A., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201211-1983oc · Cited by 529

mTOR in health and in sickness

Liko, D., & Hall, M. N. (2015) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1326-7 · Cited by 60

mTOR in aging, metabolism, and cancer

Cornu, M., Albert, V., & Hall, M. N. (2013) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2012.12.005 · Cited by 455

mTOR Signaling in Growth, Metabolism, and Disease

Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555

[TOR-centric concept of regulation mitogenic, metabolic and energetic signal processing in cell].

Zubova, S. G., Shitikova, Z. V., & Tv, P. (2012) · PubMed · Cited by 5

mTOR: from growth signal integration to cancer, diabetes and ageing

Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941